I HEREBY CERNIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY: Katie C. Kinsman DATE: October 2, 2001

PATENT BOX SEQUENCE

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application of

: Group Art Unit: Not Yet Assigned

Rocio M. Sierra-Honigmann

Appln. No.:

09/700,813

Examiner: Kaya Baltimore

Filed:

May 20, 1999

For:

MODULATION OF ANGIOGENESIS

: Attorney Docket

AND WOUND HEALING

: No. 044574-5029

# STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- (X) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- (X) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.
- ( ) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheets of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute sheets(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.

1-PH/1489705.1

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

#### ROCIO SIERRA-HONIGMANN et al.

October 1, 1001 (Date) By: Lafton Dayle KATHRYN DOYLE, Ph.D, J.D.

Registration No. 36,317

MORGAN, LEWIS & BOCKIUS, LLP

1701 Market Street

Philadelphia, PA 19103-2921 Telephone: (215) 963-5000 Direct Dial: (215) 963-4723 Facsimile: (215) 963-5299

E-Mail: kdoyle@morganlewis.com

Attorney for Applicants

KD/GHL

Enclosures: Sequence Listing in Paper and Computer Readable Format

Amendment directing entry of the Sequence Listing into the specification

Copy of the Notification of Missing Requirements

#### **EXPRESS MAIL LABEL NO.: EL719365832US**

PATENT BOX PCT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application of

: Group Art Unit: Not Yet Assigned

Rocio M. Sierra-Honigmann

Appln. No.:

09/700,813

: Examiner: Kaya Baltimore

Filed:

May 20, 1999

For:

**MODULATION OF ANGIOGENESIS** 

: Attorney Docket

AND WOUND HEALING

: No. 044574-5029

# STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- (X) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- (X) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.
- ( ) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheets of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute sheets(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

### ROCIO SIERRA-HONIGMANN et al.

<u>October 5</u> 2001 (Date) By: KATHRYN DOYLE, Ph.D, J.D.

Registration No. 36,317

MORGAN, LEWIS & BOCKIUS, LLP

1701 Market Street

Philadelphia, PA 19103-2921 Telephone: (215) 963-5000 Direct Dial: (215) 963-4723 Facsimile: (215) 963-5299

E-Mail: kdoyle@morganlewis.com

KD/GHL

Attorney for Applicants

Enclosures: Sequence Listing in Paper and Computer Readable Format

Amendment directing entry of the Sequence Listing into the specification

Copy of the Notification of Missing Requirements

U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY, DOCKET NO.	
09/700813	SIERRA-HONIGMANN		R	044574-5029-
00,7000.0	INTERNATIONAL		L APPLICATION NO	
MORGAN, LEWIS & BOCKIUS 1800 M STREET NW			PCT/US99/11209	
WASHINGTON, DC 20036 5869			1.A FILING DATE	PRIORITY DATE
			20 MAY 99	20 MAY 98
			DATE MAILED	<b>05</b> SEP

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

	Kaya Baltimore
	/U3) 287-U2UU, IUI FAICHIIII SULWAIC HEIP.
9	703) 308-4212, for CRF submission help, 703) 287-0200, for PatentIn software help.
(	703) 308-4216, for Rules interpretation.
FOR QU.	ESTIONS REGARDING COMPLIANCE WITH THESE REGULARIZATION PLANTS
COD OIL	ESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
	1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
Ĺ.	are the same and, where applicable, include no new matter, as required by 37 CFR
	amendment directing its entry into the specification.  A statement that the contents of the paper or compact disc and the computer readable form
×	An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
_	An initial or substitute computer readable form (CRF) of the "Sequence Listing."
ADDI ICA	NT MUST PROVIDE:
-	
	Other:
	The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
	substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
	damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A
_	Sequence Listing."  The computer readable form that has been filed with this application has been found to be
	37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw
	A copy of the Sequence Listing in computer readable form has been adomitted. The content of the computer readable form, however, does not comply with the requirements of
_	required by 37 CFR 1.821(e).  A copy of the "Sequence Listing" in computer readable form has been submitted. The
	A copy of the "Sequence Listing" in computer readable format has not been submitted as
	disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
×	This application does not contain, a "Sequence Listing" as a separate part of the
-	The application fails to comply with the requirements of 37 CFR 1.821-1.825.

FORM PCT/DO/EO/920 (March 2001)

Telephone: 703-305-3696